Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Moodys
Fish and Richardson
Federal Trade Commission
Deloitte
US Department of Justice
Teva
Colorcon

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210428

« Back to Dashboard

NDA 210428 describes KAPSPARGO SPRINKLE, which is a drug marketed by Spil and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the KAPSPARGO SPRINKLE profile page.

The generic ingredient in KAPSPARGO SPRINKLE is metoprolol succinate. There are fifty-nine drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.
Summary for 210428
Tradename:KAPSPARGO SPRINKLE
Applicant:Spil
Ingredient:metoprolol succinate
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 210428
Mechanism of ActionAdrenergic beta-Antagonists
Suppliers and Packaging for NDA: 210428
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428 NDA Sun Pharmaceutical Industries, Inc. 10631-008 10631-008-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10631-008-30)
KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428 NDA Sun Pharmaceutical Industries, Inc. 10631-009 10631-009-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10631-009-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 25MG TARTRATE
Approval Date:Jan 26, 2018TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 9, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jul 9, 2035Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 50MG TARTRATE
Approval Date:Jan 26, 2018TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 9, 2035Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Medtronic
Harvard Business School
UBS
Express Scripts
Johnson and Johnson
Chubb
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.